Asset development is often highly centered around obtaining regulatory approval. This clinically-minded lens puts market adoption at risk. In this session, we’ll discuss how new approaches to asset development which wholistically integrate both clinical and commercial considerations can de-risk development costs, maximize uptake, and help support a better value creation narrative for investors or other key stakeholders. We’ll look at a case study of how an early stage biotech used this approach to successfully prove their asset’s worth, secure capital, and advance development. Join us as we share with you our thoughts on Rethinking Asset Development: The Power of Commercial Insights.
